Engflag

Glycomet SR

Quick links to important sections

Glycomet SR

Glycomet SR_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glycomet SR

Quick Facts Table

Property Description
Active ingredient Metformin Hydrochloride
Form Sustained-Release (SR) Oral Tablet
Pharmacological class Biguanide, Antihyperglycemic Agent
Common use Management of Type 2 Diabetes
Origin Synthetic Derivative

Defining Glycomet SR: Type and Composition

Glycomet SR is a prescription-only oral medicine primarily used to manage elevated blood sugar levels associated with Type 2 Diabetes Mellitus. It is a single-agent product whose sole active ingredient is Metformin Hydrochloride. Metformin is classified within the Biguanide group, a unique pharmacological category of antihyperglycemic agents. This chemical lineage confirms that the medication is a foundational part of managing high blood sugar.

Glycomet SR as a Sustained-Release Formulation

The SR tablet is an Extended-Release dosage form, meaning the medication is designed to be released gradually following oral ingestion. This formulation uses a specialized solid pharmaceutical matrix that controls the dissolution rate of the active compound. The controlled-release mechanism is designed to provide a more uniform, day-long therapeutic concentration, which can be an advantage over standard, immediate-release Metformin tablets. Sustained-release products are recognized for their potential to improve patient compliance and tolerance.

General Purpose of This Antihyperglycemic Agent

The fundamental purpose of Glycomet SR is to function as an antihyperglycemic agent, aiming to normalize and reduce high blood glucose concentrations. This is accomplished by acting on the metabolic processes in the body, primarily decreasing the amount of glucose produced by the liver and enhancing the tissues' ability to utilize the insulin that is already present. This class of medicine is commonly used for adults with Type 2 Diabetes where lifestyle modifications alone have not been sufficient to achieve adequate glycemic control.

Regulatory References

  1. Metformin: MedlinePlus Drug Information

What side effects are possible with Glycomet SR?

Possible Side Effects and Safety Information

Glycomet SR (metformin hydrochloride extended-release) has a safety profile officially documented by regulatory agencies, focusing primarily on metabolic and gastrointestinal considerations. The information below is strictly based on governmental prescribing labels.

Officially Listed Adverse Reactions

Common Effects

The most frequently reported adverse reactions are often related to the Gastrointestinal System and may be transient, especially upon starting therapy. These effects, which are listed as Common in regulatory documentation, include:

  • Diarrhea
  • Nausea and Vomiting
  • Abdominal pain
  • Flatulence
  • Taste disturbance (often metallic taste)

Additionally, decreased Vitamin B12 serum concentrations are documented as a common effect associated with long-term use, though clinically significant deficiency is rare.

Serious Adverse Reactions

Metformin carries a regulatory Boxed Warning for the rare but potentially fatal risk of Lactic Acidosis. This serious metabolic condition is associated with the accumulation of the drug, and its symptoms include nonspecific signs like malaise, myalgias (muscle pain), somnolence, and respiratory distress.

Safety Constraints and Considerations

The medicine's use is subject to specific constraints documented in official labeling:

  • Contraindications: Glycomet SR is strictly contraindicated in patients with severe renal impairment (eGFR below 30 mL/min/1.73 m^2) due to the heightened risk of Lactic Acidosis. It is also contraindicated in cases of metabolic acidosis.
  • Hepatic Impairment: The drug is generally avoided in patients with liver dysfunction, as this condition is a recognized risk factor for Lactic Acidosis.
  • Procedural Discontinuation: The medicine must be temporarily discontinued before or at the time of any radiological procedure involving iodinated contrast media or major surgery, as specified in regulatory documentation.

These constraints define the high-level boundaries for the drug's use.

Overdose and Emergency Response

Overdose: When to Seek Immediate Medical Help

Overdose with Glycomet SR (metformin) carries a primary and serious risk of lactic acidosis, a medical emergency that must be treated in a hospital setting. Lactic acidosis results from the buildup of too much lactic acid in the body, which can be fatal in approximately 50% of cases.

Overdose presentations range from non-specific symptoms to severe complications. Initial signs may include nausea, vomiting, abdominal pain, lethargy, and a general feeling of malaise. As the condition progresses, more marked signs of serious toxicity can develop, such as deep and rapid breathing (respiratory distress), hypothermia, hypotension (low blood pressure), increasing somnolence, and resistant bradyarrhythmias.

Immediate Action Required

If you suspect an overdose or experience any symptoms associated with lactic acidosis, you must immediately discontinue the drug and get emergency medical help right away.

Regulatory documents emphasize that prompt medical intervention is essential. The authoritative treatment to correct the acidosis and remove accumulated metformin from the body is hemodialysis.

High-Risk Factors

Patients who are elderly, dehydrated, or have existing conditions such as unstable congestive heart failure (CHF) or severe renal (kidney) dysfunction are at a particularly increased risk of developing lactic acidosis following an overdose.

Therapeutic Uses of Glycomet SR

Main Uses and Benefits of Glycomet SR

Glycomet SR is a sustained-release formulation of metformin, a medication primarily used in the management of metabolic disorders. The sustained-release mechanism is designed to release the active ingredient gradually over an extended period, which can help maintain more consistent levels of the medication in the bloodstream.

Management of Type 2 Diabetes

The primary use of Glycomet SR is the treatment of type 2 diabetes mellitus. In this condition, the body either does not produce enough insulin or cannot effectively use the insulin it produces, leading to elevated blood glucose levels. Glycomet SR assists in glucose management through several mechanisms:

  • Reduction of Hepatic Glucose Production: It limits the amount of glucose produced and released by the liver.
  • Improvement of Insulin Sensitivity: It enhances the body's sensitivity to insulin, allowing peripheral tissues like muscle and fat to absorb and utilize glucose more efficiently.
  • Slowing Intestinal Absorption: It can delay the absorption of glucose from the digestive tract into the bloodstream after meals.

Benefits Beyond Glucose Control

While its main role is blood sugar regulation, this medication is associated with several physiological benefits that support long-term metabolic health:

  • Weight Neutrality: Unlike some other glucose-lowering medications, Glycomet SR is generally weight-neutral and may, in some cases, support modest weight management efforts when combined with lifestyle changes.
  • Cardiovascular Considerations: By assisting in the stabilization of blood sugar levels, the medication plays a role in the broader management of factors associated with cardiovascular health in individuals with metabolic concerns.
  • Stability of Blood Sugar: The sustained-release delivery system is intended to reduce the frequency of gastrointestinal discomfort and provide a smoother therapeutic effect throughout the day compared to immediate-release versions.

Eligibility and Restrictions for Use

Glycomet SR is authorized for use in adults with Type 2 Diabetes Mellitus. Eligibility is determined by strict rules established in regulatory labeling, primarily centered on organ function and acute clinical status.

Contraindications: When Use is Prohibited

The medicine is contraindicated and must not be used if a patient has severe renal impairment (an estimated glomerular filtration rate, or eGFR, below 30 mL/min/1.73m^2), metabolic acidosis (including diabetic ketoacidosis), or a known hypersensitivity to Metformin. Use is also prohibited in acute conditions that cause tissue hypoxia, such as unstable heart failure, respiratory failure, or shock.

Restricted and Conditional Use

Regulatory documents outline specific restrictions for other populations. Treatment initiation is not recommended in moderate renal impairment (eGFR between 30 and 45 mL/min/1.73m^2) and should be avoided in patients with hepatic impairment. The medication must be temporarily discontinued before certain radiological procedures involving iodinated contrast media and before surgery. For the pediatric population, safety and effectiveness have not been established for the extended-release formulation in children under 18 years of age. Older adults require more frequent assessment of renal function.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Glycomet SR (Metformin HCl Extended-Release)

Property Description (Regulatory Context)
Medicinal product categories with documented interactions Other Antihyperglycemic Agents; Carbonic Anhydrase Inhibitors; Drugs with Hyperglycemic Activity (Glucocorticoids, Diuretics); Cationic Drugs Cleared by Renal Tubular Secretion.
Specific interacting medicines (if explicitly listed) Cimetidine, Ranolazine, Dolutegravir, Vandetanib, Nifedipine, Topiramate, Furosemide.
Mechanistic basis of interactions (only if stated in label) Inhibition of Renal Transporters (Organic Cation Transporter 2 ( OCT2) / Multidrug and Toxin Extrusion ( MATE)); Pharmacodynamic Additive Effects (Hypoglycemia); Interference with Lactate Metabolism (Alcohol).
Timing-based interaction rules (if applicable) Mandatory temporary discontinuation prior to, or at the time of, and for 48 hours afterward following administration of iodinated contrast agents.
Population-specific interaction notes (if applicable) Interactions resulting in Metformin accumulation pose a higher risk in patients ge 65 years old and those with pre-existing renal or hepatic impairment.
Interaction-related restrictions Must not be co-administered with excessive alcohol intake due to increased risk of lactic acidosis.
Classification Description (Regulatory Context)
Interaction severity classification (as defined in official documents) Contraindicated (with iodinated contrast in certain patient groups); Clinically Significant (exposure-altering agents); Increased Risk of Lactic Acidosis.
Regulatory basis (EMA / FDA / etc.) Based on US FDA Prescribing Information and European Summary of Product Characteristics.
Interaction-context constraints (as defined in official documents) The 48-hour timing rule is conditional on the use of iodinated contrast agents or major surgical procedures involving specific anesthesia.

Official interaction statements:

  • Iodinated Contrast Agents: Co-administration is formally contraindicated in specific patient populations due to risk of acute renal function change.
  • Renal Transporter Inhibitors: Agents like Cimetidine and Ranolazine reduce Metformin clearance by inhibiting OCT2/ MATE transporters, leading to an increase in Metformin plasma concentrations.
  • Pharmacodynamic Effects: Concomitant use with Insulin or Sulfonylureas has an officially documented additive effect, increasing the risk of hypoglycemia.
  • Alcohol: Excessive intake is explicitly documented to potentiate Metformin's effect on lactate metabolism, which formally increases the risk of lactic acidosis.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the interaction profile primarily through pharmacokinetic alterations involving renal clearance and pharmacodynamic alterations affecting metabolism or glucose control. This structure establishes specific, mandatory timing-based constraints for procedures like contrast imaging and identifies agents that formally increase Metformin exposure or raise the risk of lactic acidosis.

Mechanism of Action

How Glycomet SR Works

Glycomet SR (metformin) influences multiple cellular and molecular pathways that regulate glucose metabolism. Its primary site of action is the liver, followed by muscle and the gastrointestinal tract.

Metformin engages mechanisms that regulate gluconeogenesis, the process by which the liver produces glucose. The drug non-competitively inhibits key enzymatic steps in this pathway, such as those involving mitochondrial glycerophosphate dehydrogenase, thereby altering the rate of glucose synthesis and release from the hepatocyte.

Simultaneously, it initiates the activation of AMP-activated protein kinase (AMPK) within the cell. This modification of the cellular energy sensor leads to altered lipid and glucose metabolism, resulting in increased insulin sensitivity and glucose uptake by peripheral tissues. In the gastrointestinal system, the drug modifies glucose absorption dynamics by affecting the uptake of dietary glucose from the intestines.

Dosage and Administration Information

Administration Guidelines for Glycomet SR (Metformin Extended-Release)

Glycomet SR is a prolonged-release tablet and must be taken as prescribed, following instructions for use, dosing, and administration conditions.

Administration Scope Instruction
Route of Administration Oral ingestion only.
Starting Dose (Adult) 500 mg taken once daily (qDay).
Timing in relation to Meals Must be taken with the evening meal.
Preparation Requirements The tablet must be swallowed whole. Do not crush, cut, or chew the tablet to ensure the proper sustained release mechanism.
Dose Titration The dose is typically increased in increments of 500 mg no more often than every 1 to 2 weeks, based on tolerability. The maximum recommended dose for once-daily administration is 2000 mg.
Missed Dose If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. Do not take two doses at the same time.
Renal Function Restrictions Prior to initiation, renal function (eGFR) must be assessed. The medicine is contraindicated in patients with an eGFR below 30 mL/min/1.73 m^2, and initiation is not recommended for patients with an eGFR between 30 and 45 mL/min/1.73 m^2.

For procedures involving iodinated contrast imaging, the medicine may need to be temporarily discontinued at the time of or prior to the procedure and should only be restarted 48 hours later if renal function is stable.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Glycomet SR

Research into this medicine focuses on two main areas: the study of changes in blood sugar markers in the short term, and the long-term observational data gathered on the class of drug. The findings describe group patterns observed in research, and evidence provides context but does not offer individual predictions.

Evidence for Glycemic Control in Type 2 Diabetes

Research examined the sustained-release (SR) formulation primarily through Randomized Controlled Trials (RCTs). These studies explored how the drug was observed in adults with Type 2 Diabetes Mellitus (T2DM). The primary outcomes monitored were biomarkers such as Glycated Hemoglobin (HbA1c) levels and Fasting Plasma Glucose (FPG). Findings described patterns of HbA1c measurements when comparing the SR and immediate-release (IR) formulations.

While the metformin drug class has a large volume of research, follow-up durations were limited in many of the direct comparative trials between the SR and IR versions. Therefore, the available comparative evidence primarily provides insight into short-term changes. Data for certain groups remain insufficient, particularly for those with varying symptom burdens.

Research on Long-Term Metabolic and Cardiovascular Outcomes

Long-term research on the use of this drug class was evaluated in large-scale prospective trials with follow-up periods that extended over many years. This research was applied in observational settings evaluating long-term health markers.

Studies monitored major health outcomes over time, including the incidence of Major Adverse Cardiovascular Events (MACE) and all-cause mortality. Findings describing patterns observed in these long-term studies related to the incidence of certain diabetes-related complications. These studies were reported to have often focused on overweight adults with T2DM.

However, the most comprehensive and foundational long-term data regarding cardiovascular outcomes was generated using the immediate-release (IR) formulation of metformin. Therefore, evidence from trials that have exclusively followed the SR formulation for long-term health markers is not as extensive. Certainty remains low for some of the longer-term measured outcomes.

Key Studies & References

  1. Long-Acting Metformin Vs. Metformin Immediate Release in Patients With Type 2 Diabetes: A Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Glycomet SR (FAQ)

Q: Can I take Glycomet SR if I am pregnant or breastfeeding?

Regulatory documents confirm that Metformin is known to cross the placenta during pregnancy. Because experts often prefer insulin for managing high blood sugar in this condition, official information suggests this medicine should only be used if a healthcare provider determines the potential benefit is clearly warranted. For breastfeeding, limited data show the drug is present in human milk. Due to insufficient information on effects in the nursing infant, a decision must be made, in consultation with a healthcare provider, to either stop taking the medicine or stop breastfeeding.

Q: How long does the GI (stomach) side effect (e.g., diarrhea) last after I start taking the drug?

Official product information notes that gastrointestinal side effects, such as nausea and diarrhea, are most frequently reported when starting the therapy or increasing the dosage. The information indicates these effects are often transient, meaning they are typically temporary and may lessen over time. This is why the dose is generally increased slowly over several weeks.

Q: What happens if I take Glycomet SR on an empty stomach instead of with my evening meal?

The official administration guidelines stipulate that this medicine must be taken with the evening meal. This requirement is intended to support the drug's sustained-release mechanism and to potentially help reduce the common gastrointestinal side effects. Taking the drug on an empty stomach may alter its absorption dynamics and is associated with a higher likelihood of experiencing these stomach-related adverse reactions.

How should Glycomet SR be stored and disposed of?

How to Store and Dispose of Glycomet SR

Official regulatory information requires that Glycomet SR (Metformin Extended-Release) be stored to maintain its quality and stability.

Storage Requirements

The product must be kept in its original, tightly closed container in a cool and dry place at controlled room temperature (e.g., below 30 C).

Storage Restriction Requirement
Environment Protect from direct sunlight, excess heat, and moisture.
Safety Must be stored out of the sight and reach of children and pets.

Disposal Requirements

To dispose of unused or expired Glycomet SR, do not keep outdated medicine. Consult a pharmacist or doctor for instructions on proper disposal. This procedure ensures the safe and environmentally responsible removal of the medication, as recommended by official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Glycomet SR found in:

A-Z Index: